FindTrial
Sign In

Model Identification and Management Application Research on High-Risk Populations for Discontinuation of Biological Therapy in Patients with Moderate-to-Severe Psoriasis

Model Identification and Management Application Research on High-Risk Populations for Discontinuation of Biological Therapy in Patients with Moderate-to-Severe Psoriasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124710
Enrollment
Unknown
Registered
2026-05-15
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Interruption Treatment Group vs Non-Interruption Treatment Group:None

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with moderate to severe psoriasis or psoriatic arthritis. The diagnostic criteria refer to the definition in the 'Guidelines for the Diagnosis and Treatment of Psoriasis' (2023 Edition). 2.Received treatment with biologic drugs. Biologics include etanercept, infliximab, adalimumab, secukinumab, ustekinumab, ixekizumab, rituximab, brodalumab, guselkumab, tildrakizumab, and peficitinib.

Exclusion criteria

Exclusion criteria: 1.More than 20% of the medical treatment information for previously diagnosed patients is missing.

Design outcomes

Primary

MeasureTime frame
Interruption Treatment;—

Secondary

MeasureTime frame
Accuracy, specificity, positive predictive value, negative predictive value, kappa value, C-statistic, calibration curve, decision curve analysis;Economic condition;—

Countries

China

Contacts

Public ContactFei Zhao

Beijing Hospital

zhaofei21cn@126.com+86 10 85133648

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026